Q-omics provides the consensus-scored DCAF7 profile across patient tissues and cancer cell-line models. DCAF7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DCAF7 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DCAF7 protein abundance shows 28,969 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where DCAF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF7 survival associations across molecular data types. DCAF7 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF7 RNA expression–survival associations across cancer types. High DCAF7 expression shows unfavorable associations in ACC, LIHC, MESO and KICH, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DCAF7 RNA expression.
This table summarizes DCAF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DCAF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF7 shows lower tumor expression in KICH and higher tumor expression in HNSC, STAD, BLCA, LIHC and BRCA. The HNSC box plot shows higher DCAF7 RNA expression in tumor versus normal tissue (log2 FC = +0.887, t-test p < 0.001).
This table shows molecular features associated with DCAF7 in patient tissues and cancer cell lines. In patient samples, DCAF7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
